AngioDynamics designs, manufactures and sells medical, surgical and diagnostic devices for the treatment of peripheral vascular disease, vascular access and for use in oncology and surgical settings. The company's business units are: Oncology/Surgery, which provides a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the NanoKnife System; Vascular Interventions and Therapies, which supports the medical areas of venous insufficiency, thrombus management, and peripheral products; and Vascular Access, which includes peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters and related accessories and supplies.

Great Western Bancorp is a bank holding company focused on relationship-based business and agri-business banking. The company serves its customers through branches in Arizona, Colorado, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota and South Dakota. The company focuses on business banking, complemented by its agri-business banking, retail banking and wealth management services. The company's loan portfolio consists mainly of business loans, comprised of commercial real estate loans and commercial non-real estate loans. The company also provides a range of deposit and loan products to its retail customers. The company is engaged in private banking, financial planning, investment management and insurance operations.

Knowles is a provider of micro-acoustic, audio processing and precision device solutions, serving the mobile consumer electronics, communications, medtech, defense, automotive, and industrial markets. The company is organized into two reportable: Audio, which designs and manufactures audio products, including microphones and balanced armature speakers, audio processors, and software and algorithms used in applications that serve the mobile, ear, and Internet of Things markets; and Precision Devices, which is focused on the design and delivery of capacitor products and mmWave radio frequency solutions.

Navient is a provider of education loan management and business processing solutions. The company's segments include: Federal Education Loans, in which the company holds and acquires Federal Family Education Loan Program Loans and performs servicing and asset recovery services on its own loan portfolio, federal education loans owned by the United States Department of Education and other institutions; Consumer Lending, in which the company holds, originates and acquires consumer loans and performs servicing activities on its own education loan portfolio; and Business Processing, which performs revenue cycle management and business processing services for non-education related government and healthcare clients.

NGM Biopharmaceuticals is a biopharmaceutical company. The company is focused on the following programs: Aldafermin, which is for the treatment of non-alcoholic steatohepatitis (NASH); NGM313 (MK-3655), which is for the treatment of NASH and type 2 diabetes; NGM120, which is designed to block the effects of elevated growth differentiation factor 15 levels on cancer anorexia/cachexia syndrome, and, possibly, tumors; NGM217, which is designed to restore pancreatic islet function and increase insulin production in patients with diabetes; NGM621, which is designed to decrease levels of this protein implicated in the dry form of AMD; and NGM395, which is for the treatment of metabolic syndrome.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

Pluristem Therapeutics is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company's product candidates include: PLX-PAD, which is in a multinational clinical trial in critical limb ischemia, and in a multinational clinical trial in recovery following surgery for hip fracture; PLX-R18, which is under development in the United States for acute radiation syndrome, as well as in a trial in the United States and Israel for incomplete hematopoietic recovery following hematopoietic cell transplantation; and PLX-Immune, which is under pre-clinical development for treatment of certain types of human cancer.

Washington Federal is a bank holding company. Through its subsidiary, Washington Federal, National Association, the company's business consists of accepting deposits from the general public and investing these funds in loans of several types, including first lien mortgages on single-family dwellings, construction loans, land acquisition and development loans, loans on multi-family, commercial real estate and other income producing properties, home equity loans and business loans. The company invests in certain United States government and agency obligations and other investments permitted by applicable laws and regulations. Through its subsidiaries, the company is also engaged in insurance brokerage activities.